As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...

Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The biotech, renowned for its pioneering development of vaccines based on ...

Moderna is the only company in its peer group burning cash at an alarming rate. Click here to read more about MRNA stock and ...

Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...

The pandemic accelerated Moderna's evolution into a commercial-stage biotech, and we expect that the firm's ramp-up in manufacturing and clinical know-how will pave the way for faster timelines ...

TUESDAY, Jan. 21, 2025 (HealthDay News) -- The U.S. Department of Health and Human Services (HHS) is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to ...

Moderna (NASDAQ: MRNA ... That seems like a very reasonable price when you consider commercial-stage biotech stocks tend to trade for mid-single-digit multiples of trailing-12-month sales.

it is clear that the past year brought formidable challenges for Moderna along with significant advances, particularly for our development pipeline. It was a year of navigating a dynamic global ...

With only one commercial product – the COVID-19 vaccine – Moderna faces pressure to diversify its pipeline rapidly. As the company invests heavily in expanding its non-COVID mRNA vaccine ...